Marvel Biosciences Corp.
MRVL.V
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.50% | -5.30% | -23.80% | -34.88% | -36.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.38% | -33.55% | -45.94% | -57.41% | -44.85% |
| Operating Income | -18.38% | 33.55% | 45.94% | 57.41% | 44.85% |
| Income Before Tax | -31.35% | 25.94% | 35.51% | 44.59% | 29.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.35% | 25.94% | 35.51% | 44.59% | 29.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.35% | 25.94% | 35.51% | 44.59% | 29.02% |
| EBIT | -18.38% | 33.55% | 45.94% | 57.41% | 44.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -7.26% | 31.81% | 39.02% | 46.06% | 29.53% |
| Normalized Basic EPS | -6.32% | 32.11% | 38.91% | 46.08% | 29.10% |
| EPS Diluted | -7.26% | 31.81% | 39.02% | 46.06% | 29.53% |
| Normalized Diluted EPS | -6.32% | 32.11% | 38.91% | 46.08% | 29.10% |
| Average Basic Shares Outstanding | 18.41% | 11.10% | 6.73% | 3.59% | 0.76% |
| Average Diluted Shares Outstanding | 18.41% | 11.10% | 6.73% | 3.59% | 0.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |